Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme, a Sanofi company and Veracyte, have entered into a global co-promotion partnership to provide a comprehensive solution for thyroid patients.
Subscribe to our email newsletter
Under terms of the agreement, Genzyme will market and promote Veracyte’s Afirma Thyroid FNA Analysis, a novel approach for improved thyroid nodule diagnosis, in the US and, subsequently, in global markets.
Financial terms of the deal have not been disclosed.
Veracyte’s solution combines expert cytopathology assessment of thyroid nodule FNA samples with Afirma Gene Expression Classifier used to resolve indeterminate results and help patients with benign nodules avoid unnecessary surgery.
Two independent clinical studies have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as benign with the same degree of accuracy as a benign cytopathology diagnosis.
Veracyte cofounder and CEO Bonnie Anderson said that their solution will improve the cost-effectiveness of thyroid nodule diagnosis worldwide.
"This partnership will enable us to utilize Genzyme’s endocrinology sales force and marketing infrastructure to commercialize our Afirma Thyroid FNA Analysis more quickly in the U.S. and globally," Anderson added.